Literature DB >> 8076698

Levels of normal and abnormally phosphorylated tau in different cellular and regional compartments of Alzheimer disease and control brains.

S Khatoon1, I Grundke-Iqbal, K Iqbal.   

Abstract

Microtubule associated protein tau is abnormally phosphorylated in Alzheimer disease (AD) brain. In the present study we investigated (i) whether tau is axonal or both axonal and somatodendritic, (ii) whether tau is a marker of Alzheimer neurofibrillary pathology, and (iii) whether the levels of tau in the cytosol (100,000 x g supernate) from AD brain are altered. Frozen autopsied tissue from 20 AD, 17 normal aged and 15 neurological control cases obtained 3-8 h postmortem were analyzed. Levels of normal, total, and abnormally phosphorylated tau were determined by a radioimmunoslot-blot assay using mAb Tau-1 as the primary antibody. Both frontal gray matter homogenate and cytosol from normal brains had 30-45% higher levels of normal tau than the corresponding fractions from the white matter. In AD frontal and temporal cortices, the total tau levels were 6- to 7-fold higher than in cerebellar cortex (P < 0.01 and P < 0.02). Furthermore, tau levels of cerebellar cortex, an area of the brain unaffected with Alzheimer neurofibrillary changes, were indistinguishable between AD and control groups. The levels of normal tau in cytosol from both frontal gray and white matters in AD were reduced by approximately 40% (P < 0.05). The levels of total tau in AD frontal and temporal cortex were 4- to 5-fold higher than in the corresponding tissue from control cases (P < 0.01) and this increase was in the form of abnormally phosphorylated tau. These studies suggest (i) that there is probably at least as much tau in the somatodendritic compartment as in the axonal compartment, (ii) that the abnormally phosphorylated tau is a biochemical marker of the neurofibrillary pathology in AD, and (iii) that the levels of normal tau are significantly reduced in the 100,000 x g brain supernate from AD cases.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8076698     DOI: 10.1016/0014-5793(94)00829-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  62 in total

1.  Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export.

Authors:  Peng Lei; Scott Ayton; David I Finkelstein; Loredana Spoerri; Giuseppe D Ciccotosto; David K Wright; Bruce X W Wong; Paul A Adlard; Robert A Cherny; Linh Q Lam; Blaine R Roberts; Irene Volitakis; Gary F Egan; Catriona A McLean; Roberto Cappai; James A Duce; Ashley I Bush
Journal:  Nat Med       Date:  2012-01-29       Impact factor: 53.440

2.  Nucleation-dependent tau filament formation: the importance of dimerization and an estimation of elementary rate constants.

Authors:  Erin E Congdon; Sohee Kim; Jonathan Bonchak; Tanakorn Songrug; Anastasios Matzavinos; Jeff Kuret
Journal:  J Biol Chem       Date:  2008-03-21       Impact factor: 5.157

3.  Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation.

Authors:  Patrick Reilly; Charisse N Winston; Kelsey R Baron; Margarita Trejo; Edward M Rockenstein; Johnny C Akers; Najla Kfoury; Marc Diamond; Eliezer Masliah; Robert A Rissman; Shauna H Yuan
Journal:  Neurobiol Dis       Date:  2017-06-10       Impact factor: 5.996

4.  Pathogenic missense MAPT mutations differentially modulate tau aggregation propensity at nucleation and extension steps.

Authors:  Edward Chang; Sohee Kim; Haishan Yin; Haikady N Nagaraja; Jeff Kuret
Journal:  J Neurochem       Date:  2008-09-18       Impact factor: 5.372

5.  Lithium suppression of tau induces brain iron accumulation and neurodegeneration.

Authors:  P Lei; S Ayton; A T Appukuttan; S Moon; J A Duce; I Volitakis; R Cherny; S J Wood; M Greenough; G Berger; C Pantelis; P McGorry; A Yung; D I Finkelstein; A I Bush
Journal:  Mol Psychiatry       Date:  2016-07-12       Impact factor: 15.992

Review 6.  Melatonin in Alzheimer's Disease: A Latent Endogenous Regulator of Neurogenesis to Mitigate Alzheimer's Neuropathology.

Authors:  Md Farhad Hossain; Md Sahab Uddin; G M Sala Uddin; Dewan Md Sumsuzzman; Md Siddiqul Islam; George E Barreto; Bijo Mathew; Ghulam Md Ashraf
Journal:  Mol Neurobiol       Date:  2019-06-17       Impact factor: 5.590

Review 7.  Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer's disease from a ferroptosis perspective.

Authors:  Paul J Derry; Muralidhar L Hegde; George R Jackson; Rakez Kayed; James M Tour; Ah-Lim Tsai; Thomas A Kent
Journal:  Prog Neurobiol       Date:  2019-10-08       Impact factor: 11.685

8.  Mammalian target of rapamycin (mTor) mediates tau protein dyshomeostasis: implication for Alzheimer disease.

Authors:  Zhi Tang; Erika Bereczki; Haiyan Zhang; Shan Wang; Chunxia Li; Xinying Ji; Rui M Branca; Janne Lehtiö; Zhizhong Guan; Peter Filipcik; Shaohua Xu; Bengt Winblad; Jin-Jing Pei
Journal:  J Biol Chem       Date:  2013-04-12       Impact factor: 5.157

9.  D-Ribosylated Tau forms globular aggregates with high cytotoxicity.

Authors:  Lan Chen; Yan Wei; Xueqing Wang; Rongqiao He
Journal:  Cell Mol Life Sci       Date:  2009-06-11       Impact factor: 9.261

Review 10.  Mechanisms of tau-induced neurodegeneration.

Authors:  Khalid Iqbal; Fei Liu; Cheng-Xin Gong; Alejandra Del C Alonso; Inge Grundke-Iqbal
Journal:  Acta Neuropathol       Date:  2009-01-30       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.